Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
终止
1
100.0%
暂无批准数据
- Champions Oncology will present eight poster presentations at the 2026 AACR Annual Meeting demonstrating how clinically relevant models can reduce translational risk in oncology drug development. - The research spans key cancer areas including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates, and CAR-T therapies. - The studies utilize patient-derived models combined with integrated molecular, functional, and phenotypic data to improve therapeutic response prediction and identify actionable biomarkers. - The company aims to help biopharma partners make more informed development decisions earlier in the pipeline by better understanding response and resistance mechanisms.
- Radiopharmaceutical development is rapidly expanding following clinical successes of Lutathera and Pluvicto, but preclinical infrastructure has not kept pace with the field's complexity. - Traditional preclinical models lack the biological complexity needed to accurately evaluate radiopharmaceutical behavior, creating a translational bottleneck in R&D programs. - Patient-derived xenograft models and advanced imaging technologies are emerging as essential tools to bridge the gap between preclinical research and clinical outcomes. - Integrated approaches combining tumor biology, nuclear imaging, and molecular profiling are becoming critical for successful radiopharmaceutical development strategies.
- The FDA released draft guidance on August 18, 2025, to help drug sponsors optimize dosing for radiopharmaceutical therapies (RPTs) in oncology clinical development programs. - The guidance allows for studying RPT dosages that exceed traditional external beam radiation therapy organ tolerance limits when adequately justified and discussed with FDA. - Radiopharmaceuticals represent an evolving cancer treatment modality that combines characteristics of both radiation therapy and systemic drug therapy, requiring specialized dosing considerations. - The new guidance provides safeguards including appropriate participant selection, trial design, safety monitoring, and radiation dosimetry evaluation for dosage optimization studies.
- Champions Oncology has appointed Rob Brainin as Chief Executive Officer effective August 25, 2025, succeeding Dr. Ronnie Morris who will transition to Executive Chair. - Brainin brings over 25 years of life sciences experience, most recently serving as Chief Business Officer at Veracyte and previously as CEO of Genuity Science. - The leadership change positions Champions to expand beyond core CRO services into robust data offerings and advance its discovery therapeutics subsidiary, Corellia AI. - Dr. Morris, who led the company since 2017, will remain actively involved in strategic initiatives while supporting the leadership transition.
- Champions Oncology has launched a fully integrated radiopharmaceutical services platform combining advanced radiochemistry infrastructure with their extensive patient-derived xenograft tumor model bank. - The company expanded its radioactive materials license to support ten key isotopes including Lu-177, Ac-225, and Y-90, enabling radioligand therapy, antibody radionuclide conjugates, and theranostic approaches. - More than thirty PDX models have been successfully screened in collaboration with pharmaceutical and biotech partners, providing clinically relevant systems for evaluating radiolabeled agents. - The platform offers integrated workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies to accelerate oncology drug development decision-making.
- Turbine has launched the world's first virtual lab using cell simulations, aligning with FDA's recent move to phase out animal testing requirements in drug development. - The platform enables scientists to simulate experimental outcomes at unprecedented speed, with initial beta modules focusing on antibody-drug conjugate (ADC) payload selection and clinical positioning. - Through a partnership with Champions Oncology, Turbine is building a virtual patient library with multi-omics data to predict therapeutic responses across diverse molecular subtypes, potentially transforming oncology R&D.
